OVERSEA CHINESE BANKING Corp Ltd Invests $30.17 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

OVERSEA CHINESE BANKING Corp Ltd bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 47,567 shares of the biopharmaceutical company’s stock, valued at approximately $30,168,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Adirondack Trust Co. increased its position in shares of Regeneron Pharmaceuticals by 4.2% during the first quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company’s stock worth $286,000 after acquiring an additional 18 shares during the last quarter. Kingswood Wealth Advisors LLC increased its holdings in Regeneron Pharmaceuticals by 1.8% in the first quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company’s stock valued at $681,000 after buying an additional 19 shares during the last quarter. Creative Financial Designs Inc. ADV increased its holdings in Regeneron Pharmaceuticals by 9.5% in the first quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company’s stock valued at $139,000 after buying an additional 19 shares during the last quarter. Private Trust Co. NA increased its holdings in Regeneron Pharmaceuticals by 13.1% in the first quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 19 shares during the last quarter. Finally, Proficio Capital Partners LLC increased its holdings in Regeneron Pharmaceuticals by 6.2% in the first quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company’s stock valued at $207,000 after buying an additional 19 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on REGN shares. The Goldman Sachs Group lowered their price objective on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating for the company in a report on Wednesday, April 30th. Morgan Stanley reissued an “overweight” rating on shares of Regeneron Pharmaceuticals in a report on Friday. Truist Financial lowered their price objective on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a “buy” rating for the company in a report on Wednesday, April 30th. BMO Capital Markets lowered their price objective on Regeneron Pharmaceuticals from $800.00 to $600.00 and set an “outperform” rating for the company in a report on Monday, June 2nd. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $850.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. One analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $837.61.

Regeneron Pharmaceuticals Stock Up 2.5%

Shares of Regeneron Pharmaceuticals stock opened at $558.87 on Friday. The business’s fifty day moving average price is $538.05 and its two-hundred day moving average price is $604.08. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. The company has a market capitalization of $60.34 billion, a P/E ratio of 14.23, a PEG ratio of 2.05 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). The business had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The firm’s revenue was down 3.7% on a year-over-year basis. During the same period in the previous year, the firm earned $9.55 EPS. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were issued a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is presently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.